Analysts Conflicted on These Healthcare Names: Ansell (OtherANSLF), Moderna (MRNA) and Humana (HUM)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ansell (ANSLF – Research Report), Moderna (MRNA – Research Report) and Humana (HUM – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ansell (ANSLF)
RBC Capital analyst Craig Wong-Pan maintained a Buy rating on Ansell yesterday and set a price target of A$41.00. The company’s shares closed last Monday at $22.74, close to its 52-week high of $23.39.
According to TipRanks.com, Wong-Pan is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Ansell with a $25.80 average price target, which is a 13.5% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a A$38.80 price target.
See today’s best-performing stocks on TipRanks >>
Moderna (MRNA)
Barclays analyst Eliana Merle maintained a Hold rating on Moderna today and set a price target of $25.00. The company’s shares closed last Friday at $42.23, close to its 52-week low of $29.25.
According to TipRanks.com, Merle is a 4-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Hold with an average price target of $32.56, representing a -22.2% downside. In a report issued on February 2, Citi also maintained a Hold rating on the stock with a $28.00 price target.
Humana (HUM)
Barclays analyst Andrew Mok CFA maintained a Hold rating on Humana today and set a price target of $245.00. The company’s shares closed last Friday at $184.10.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Humana with a $225.29 average price target, which is a 26.0% upside from current levels. In a report issued on February 12, RBC Capital also downgraded the stock to Hold with a $189.00 price target.
